Business
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update.
About this update from Evofem Biosciences, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Evofem Reports First Quarter 2026 Financial Results and Provides Business Update\r\n \r\n \r\n\r\n\r\nEvofem Reports First Quarter 2026 Financial Results and Provides Business Update\r\n\r\n\r\n\r\n\r\n\r\n\r\n— Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization —\r\n\r\n\r\n SAN DIEGO--(BUSINESS WIRE)--\r\nWomen’s health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026.\r\n\r\n\r\n \r\n“Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan Africa. We look forward to non-dilutive capital from each of these markets in 2026.”\r\n\r\n\r\n \r\nNotable advances in 2026 to-date include:\r\n\r\n\r\n \r\n \r\nExpanded our global reach into Sub-Saharan Africa through a distribution agreement with Clovis Davis Pharmaceuticals for SOLOSEC® (secnidazole) 2g oral granules.\r\n\r\n\r\n \r\nThe Emirates Drug Establishment (EDE) review of the submissions for marketing approval of PHEXX® (lactic acid, citric acid and potassium bitartrate) and SOLOSEC in the United Arab Emirates (UAE) is ongoing. The EDE issued favorable pricing certificates for PHEXX in late 2025.\r\n\r\n\r\n \r\nAdvanced patient recruitment in an investigator-led, NIH-funded Phase 4 clinical trial evaluating the effectiveness and cost-effectiveness of SOLOSEC (single-dose, one time) versus metronidazole (twice daily for seven days) for the treatment of Trichomonas vaginalis in men and women. Study investigators hypothesize that the rate of repeat infections with T. vaginalis will be 1.75 lower in the SOLOSEC group versus the multi-dose oral metronidazole arm and that single-dose SOLOSEC will have higher initial cost but will be more cost effective compared to multi-dose metronidazole, largely due to lower breakthrough rates of infection.1\r\n\r\n\r\n \r\n \r\nFirst Quarter Financial Results\r\n\r\n\r\n \r\nFor the three months ended March 31, 2026, net sales were $0.9 mill...